logo

For the Inventor, By the Inventor

Flushing, NY, United States of America

Evripidis Gavathiotis

LinkedIn

This inventor holds 19 USPTO granted patents and 14 published patent applications and 1 EPO patent, primarily in Cancer Therapeutics. Top assignees: Albert Einstein College of Medicine, University of Toronto, University of Manitoba. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Evripidis Gavathiotis. Retrieved from https://idiyas.com/inventor/evripidis-gavathiotis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Flushing, NY (US) (2016 - 2023)
  • Bronx, NY (US) (2023)
  • Roslyn, NY (US) (2022 - 2024)

Company Filing History:

goldMedal18 out of 514 
 
Albert Einstein College of Medicine
 patents
silverMedal3 out of 532 
 
University of Toronto
 patents
bronzeMedal2 out of 212 
 
University of Manitoba
 patents
4. 1 out of 621 
 
Memorial Sloan Kettering Cancer Center
 patents
where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
BAX Inhibitors
Prostaglandin Transport Inhibitors
Chaperone-Mediated Autophagy
RAF Dimers
Cancer Therapy
Mitofusin Activators
Synthetic Antibodies
Retinoic Acid Receptor Antagonists
Phenylsulfonamido-Benzofuran Derivatives
19 patents (USPTO):Explore Patents
1. 12708621 - SMALL MOLECULE BAX INHIBITORS AND USES THEREOF (2026-08-18),
2. 12630515 - Small molecule prostagladin transport inhibitors (2026-05-19),
3. 12473266 - Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators (2025-11-18),
4. 12440494 - Compounds useful for inhibiting RAF dimers (2025-10-14),
5. 12016845 - BAX activators and uses thereof in cancer therapy (2024-06-25),
6. 11938128 - Small molecule BAX inhibitors and uses thereof (2024-03-26),
7. 11834424 - Compounds useful as chaperone-mediated autophagy modulators (2023-12-05),
8. 11813268 - Mitofusin activators and uses thereof (2023-11-14),
9. 11760780 - Targeting dimerization of BAX to modulate BAX activity (2023-09-19),
10. 11591324 - Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof (2023-02-28),
11. 11382898 - BAX activators and uses thereof in cancer therapy (2022-07-12),
12. 11174308 - Synthetic antibodies to BAX and uses thereof (2021-11-16),
13. 11098021 - Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases (2021-08-24),
14. 10766886 - Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof (2020-09-08),
15. 10759851 - Synthetic antibodies to BAX and uses thereof (2020-09-01),

Title: Innovator and Inventor Evripidis Gavathiotis: Pioneering Advances in Cancer Therapy

Introduction

Evripidis Gavathiotis, an accomplished inventor based in Flushing, NY, has made significant contributions to the field of cancer therapy. With a remarkable portfolio of 15 patents, Gavathiotis has focused on developing innovative solutions that target critical aspects of cancer treatment and related disorders.

Latest Patents

Gavathiotis' latest patents include groundbreaking research on BAX activators and their uses in cancer therapy. His work on these activators aims to advance treatment options for patients battling cancer. Additionally, he has developed small molecule BAX inhibitors, providing compounds and compositions designed to inhibit BAX in diseases where such inhibition is beneficial, including cardiovascular diseases and disorders.

Career Highlights

Throughout his career, Evripidis Gavathiotis has held positions at esteemed institutions, including Albert Einstein College of Medicine and the University of Toronto. His remarkable academic background and dedication to research have positioned him as a key figure in the scientific community focused on translating innovative ideas into practical therapies.

Collaborations

Gavathiotis has had the privilege of collaborating with notable scientists, including Ana Maria Cuervo and Qisheng Xin. These partnerships exemplify the importance of collaboration in advancing innovative research and the sharing of knowledge in the pursuit of medical breakthroughs.

Conclusion

Evripidis Gavathiotis continues to push the boundaries of cancer research and therapy through his inventions and collaborations. With a focus on developing new therapeutic approaches, his work not only advances scientific understanding but also offers hope for improved treatment options for patients facing challenging health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…